Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2022

View Archived Issues

Identification of sites of metabolic liability for KRM-II-81 and evaluation of a deuterated analogue

Variant in the CTR1 gene causes novel disorder of copper metabolism

MK-6158: sGC stimulator clinical candidate for pulmonary arterial hypertension

Novel nonhallucinogenic DMT analogues as drug candidates for mental health and addiction disorders

Phosphatidylserine is crucial for synaptic pruning in adult-born neurons

New antibacterials identified at Roche

Yale University divulges new oligosaccharyltransferase complex inhibitors

HDAC inhibitors disovered at Chong Kun Dang Pharmaceutical

Dompe Farmaceutici describes new peptides with angiogenic activity

Bayer patents P2X purinoceptor 4 antagonists

Novel USP30 inhibitors as potential anti-Parkinson candidates

Novartis details discovery, preclinical data of novel antimalarial compound INE-963

Sosei Heptares' GLP-1/2 agonist HTL-0030023 shows promising results for treating NAFLD and NASH

Missense variants in DDX39B linked to novel syndrome of global neurodevelopmental delay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...